 |
|
Hormone Replacement Therapy and Breast Cancer Risk
R. Don Gambrell, Jr, MD
Arch Fam Med. 1996;5(6):341-348.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995;45:8-30.
FREE FULL TEXT
2. Annual Cancer Statistics Review. Bethesda, Md: National Institutes of Health; 1987:111-36. NIH publication 88-2789. 3. Burch JC, Byrd BF Jr, Vaughn WK. Results of estrogen treatment in one thousand hysterectomized women for 14,318 years. In: VanKeep PA, Greenblatt RB, Albeaux-Fernet M, eds. Consensus on Menopause Research. Lancaster, England: MTP Press Ltd; 1976:164-169. 4. Bergkvist L, Adami H-O, Persson I, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol. 1989;130:221-228.
FREE FULL TEXT
5. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol. 1990;97:1080-1086.
PUBMED
6. Strickland DM, Gambrell RD Jr, Butzin CA, et al. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol. 1992;80:400-404.
PUBMED
7. Gambrell RD Jr. Proposal to decrease the risk and improve the prognosis of breast cancer. Am J Obstet Gynecol. 1984;150:119-128.
PUBMED
8. Lauritzen C, Meier F. Risks of endometrial and mammary cancer morbidity and mortality in long-term oestrogen treatment. In: van Herendael H, van Herendael B, Riphagen FE, et al, eds. The Climacteric: An Update. Lancaster, England: MTP Press Ltd; 1984:207-216. 9. Colditz GA, Stampfer MJ, Willett WC, et al. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA. 1990;264:2468-2473.
10. Henderson BE, Paganinni-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75-78.
FREE FULL TEXT
11. Craig TJ, Comstock GW, Geiser PB. Epidemiologic comparison of breast cancer patients with early and late onset of malignancy and general population controls. J Natl Cancer Inst. 1974;53:1577-1581.
PUBMED
12. Boston Collaborative Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med. 1974;290:15-19.
PUBMED
13. Henderson BE, Powell D, Rosario I, et al. An epidemiologic study of breast cancer. J Natl Cancer Inst. 1974;53:609-614.
PUBMED
14. Mack TM, Henderson BE, Gerkins VR, Arthur M, Baptista J, Pike MC. Reserpine and breast cancer in a retirement community. N Engl J Med. 1975;292:1366-1371.
ABSTRACT
15. Hoover R, Gray LA Sr, Cole P, MacMahon B. Menopausal estrogens and breast cancer. N Engl J Med. 1976;295:401-405.
ABSTRACT
16. Casagrande J, Gerkins V, Henderson BE, Mack T, Pike MC. Brief communication: exogenous estrogens and breast cancer in women with natural menopause. J Natl Cancer Inst. 1976;56:839-841.
PUBMED
17. Byrd BF Jr, Burch JC, Vaughn WK. The impact of long term estrogen support after hysterectomy. Ann Surg. 1977;185:574-579.
PUBMED
18. Sartwell PE, Arthes FG, Tonascia JA. Exogenous hormones, reproductive history, and breast cancer. J Natl Cancer Inst. 1977;59:1589-1592.
PUBMED
19. Wynder EL, MacCormack FA, Stellman SD. The epidemiology of breast cancer in 785 United States Caucasian women. Cancer. 1978;41:2341-2354.
PUBMED
20. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy, II: neoplasia. Am J Obstet Gynecol. 1979;133:537-547.
PUBMED
21. Ravnihar B, Seigel DG, Lindtner J. An epidemiologic study of breast cancer and benign breast neoplasias in relation to oral contraceptive and estrogen use. Eur J Cancer Clin Oncol. 1979;15:395-405.
22. Volker W. Estrogen and estrogen-progestogen compounds: is there a risk for the development of endometrial and breast cancer in the perimenopausal woman? In: Pasetto N, Paoletti R, Ambrus JL, eds. The Menopause and Postmenopause. Lancaster, England: MTP Press Ltd; 1980: 273-288. 23. Jick H, Walker AM, Watkins RN, et al. Replacement estrogens and breast cancer. Am J Epidemiol. 1980;112:586-594.
FREE FULL TEXT
24. Bland KI, Buchanan JB, Weisberg BF, Hagan TA, Gray LA Sr. The effects of exogenous estrogen replacement therapy of the breast: breast cancer risk and mammographic parenchymal patterns. Cancer. 1980;45:3027-3033.
PUBMED
25. Ross RK, Paganinni-Hill A, Gerkins VR, et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA. 1980;243:1635-1639.
FREE FULL TEXT
26. Hoover R, Glass A, Finkle WD, Azevedo D, Milne K. Conjugated estrogens and breast cancer risk in women. J Natl Cancer Inst. 1981;67:815-820.
PUBMED
27. Brinton LA, Hoover RN, Szklo M, Fraumeni JF Jr. Menopausal estrogen use and risk of breast cancer. Cancer. 1981;47:2517-2522.
PUBMED
28. Kelsey JL, Fischer DB, Holford TR, et al. Exogenous estrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst. 1981;67:327-333.
PUBMED
29. Thomas DB, Persing JP, Hutchinson WB. Exogenous estrogens and other risk factors for breast cancer in women with benign breast disease. J Natl Cancer Inst. 1982;69:1017-1025.
PUBMED
30. Vakil DV, Morgan RW, Halliday M. Exogenous estrogens and development of breast and endometrial cancer. Cancer Detect Prev. 1983;6:415-424.
PUBMED
31. Gambrell RD Jr, Maier RC, Sanders Bl. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol. 1983;62:435-443.
PUBMED
32. Sherman B, Wallace R, Bean J. Estrogen use and breast cancer: interaction with body mass. Cancer. 1983;51:1527-1531.
PUBMED
33. Kaufman DW, Miller DR, Rosenberg L, et al. Noncontraceptive estrogen use and the risk of breast cancer. JAMA. 1984;252:63-67.
FREE FULL TEXT
34. Horwitz RI, Stewart KR. Effect of clinical features on the association of estrogens and breast cancer. Am J Med. 1984;76:192-198.
PUBMED
35. Hiatt RA, Bawol R, Friedman GD, Hoover R. Exogenous estrogen and breast cancer after bilateral oophorectomy. Cancer. 1984;54:139-144.
PUBMED
36. Talamini R, LaVecchia C, Franceschi S, et al. Reproductive and hormonal factors and breast cancer in a northern Italian population. Int J Epidemiol. 1985;14:70-74.
FREE FULL TEXT
37. Nomura AMY, Kolonel LN, Hirotata T, Lee J. The association of replacement estrogens with breast cancer. Int J Cancer. 1986;37:49-53.
PUBMED
38. McDonald JA, Weiss NS, Daling JR, Francis AM, Polissar L. Menopausal estrogen use and the risk of breast cancer. Breast Cancer Res Treat 1986;7:193-199.
PUBMED
39. Brinton LA, Hoover R, Fraumeni JF Jr. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer. 1986;54:825-832.
PUBMED
40. Buring JE, Hennekens CH, Lipnick RJ, et al. A prospective cohort study of postmenopausal hormone use and risk of breast cancer in US women. Am J Epidemiol. 1987;125:939-947.
FREE FULL TEXT
41. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA. 1987;257:209-215.
FREE FULL TEXT
42. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol. 1987;94:620-635.
PUBMED
43. Armstrong BK: Oestrogen therapy after menopause: boon or bane? Med J Aust. 1988;148:213-214.
PUBMED
44. Rohan TE, McMichael AJ. Non-contraceptive exogenous oestrogen therapy and breast cancer. Med J Aust. 1988;148:217-221.
PUBMED
45. Ewertz M. Influence of noncontraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer. 1988;42:832-838.
PUBMED
46. Brownson RC, Blackwell CW, Pearson DK, Reynolds RD, Richens JW, Papermaster BW. Risk of breast cancer in relation to cigarette smoking. Arch Intern Med. 1988;148:140-144.
FREE FULL TEXT
47. Dupont WD, Page DL, Rogers LW, Parl FF. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer. 1989;63:948-957.
PUBMED
48. Mills PK, Beeson WL, Phillips RL, Fraser GE. Prospective study of exogenous hormone use and breast cancer in Seventh-Day Adventists. Cancer. 1989;64:591-597.
PUBMED
49. Bergkvist L, Adami H-0, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 1989;321:293-297.
ABSTRACT
50. Bates SK. Postmenopausal estrogen replacement therapy and breast cancer. J Soc Obstet Gynaecol Canada. 1990;12:9-12.
51. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med. 1991;151:67-72.
FREE FULL TEXT
52. Steinberg KK, Thacker SB, Smith J, et al. A metaanalysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265:1985-1990.
FREE FULL TEXT
53. Kaufman DW, Palmer JR, deMouzon J, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol. 1991;134:1375-1385.
FREE FULL TEXT
54. Palmer JR, Rosenberg L, Clarke A, Miller DR, Shapiro S. Breast cancer risk after estrogen replacement therapy: results from the Toronto breast cancer study. Am J Epidemiol. 1991;134:1386-1395.
FREE FULL TEXT
55. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras A, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol. 1992;79:286-294.
PUBMED
56. LaVecchia C. Oestrogen replacement treatment and breast cancer: update of an Italian casecontrol study. In: Mann RD, ed. Hormone Replacement Therapy and Breast Cancer Risk. Park Ridge, NJ: The Parthenon Publishing Group Ltd; 1992:107-116. 57. Hulka BS, Schildkraut JM. North Carolina studies of oestrogens, oestrogen receptors and breast cancer. In: Mann RD, ed. Hormone Replacement Therapy and Breast Cancer Risk. Park Ridge, NJ: The Parthenon Publishing Group Ltd; 1992: 155-172. 58. Nachtigall MJ, Smilen SW, Nachtigall RD, Nachtigall RH, Nachtigall LE. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol. 1992;80:827-830.
PUBMED
59. Persson I, Yuen J, Bergkvist L, Adami H-O, Hoover R, Schairer C. Combined oestrogen-progestogen replacement and breast cancer risk. Lancet. 1992;340:1044.
PUBMED
60. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol. 1993;168:1473-1480.
PUBMED
61. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer. Cancer Causes Control. 1994;5:491-500.
PUBMED
62. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-1593.
FREE FULL TEXT
63. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995;274:137-142.
FREE FULL TEXT
64. Gambrell RD Jr. Use of progestogen therapy. Am J Obstet Gynecol. 1987;156:1304-1313.
PUBMED
65. Lauritzen C. Ostrogensubstitution in der postmenopause vor und nach behandeltem genitalund mammakarzinom. Menopause Hormonsubstitution Heute. 1993;6:76-88.
66. Coulan CB, Annegers JF. Chronic anovulation may increase breast cancer risk. JAMA. 1983;249:445-446.
FREE FULL TEXT
67. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol. 1981;114:209-217.
FREE FULL TEXT
68. Ron E, Lunenfeld B, Menezer J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1987;125:780-790.
FREE FULL TEXT
69. Buzdar AU. Progestins in cancer treatment. In: Stoll BA, ed. Endocrine Management of Cancer. Basel, Switzerland: S Karger AG; 1988:1-15. 70. Hortobagyi GN, Hug V, Buzdar AU, Kau SW, Holmes FA, Fritsche HA. Sequential cyclic combined hormonal therapy for metastatic breast cancer. Cancer. 1989;64:1002-1006.
PUBMED
71. Voherr H. Oral contraceptives and hormone replacement therapy: are progestogens and progestins breast mitogens? Am J Obstet Gynecol. 1986;155:1140-1142.
PUBMED
72. Badwe RA, Gregory WN, Chaudry MN, et al. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet. 1991;337:1261-1264.
PUBMED
73. Senie RT, Rosen PP, Phodes P, Lesser ML. Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann Intern Med. 1991;115:337-342.
FREE FULL TEXT
74. Chang KJ, Lee TTY, Linares-Cruz G, Fournier S, de Lignieres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 1995;63:785-791.
PUBMED
75. Jones B, Russo J. Influence of steroid hormones on the growth fraction of human breast carcinoma. Am J Clin Pathot 1987;88:132-138.
76. Eden JA, Bush T, Nand S, Wren BG. A case-controlled study of combined continuous estrogen-progestin replacement therapy amongst women with a personal history of breast cancer. Menopause J North Am Menopause Soc. 1995;2:67-72.
77. Cobleigh MA, Berris RF, Bush T, et al. Estrogen replacement therapy in breast cancer survivors: a time for change. JAMA. 1994;272:540-545.
FREE FULL TEXT
78. Stoll BA, Parbhoo S. Treatment of menopausal symptoms in breast cancer patients. Lancet. 1988;1:1278-1279.
PUBMED
79. DiSaia PJ, Creasman WT, Odicino F, et al. Hormone replacement therapy in breast cancer. Lancet. 1993;342:1232.
PUBMED
80. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg. 1993;165:372-375.
PUBMED
81. Powles TJ, Hickish T, Casey S, et al. Hormone replacement after breast cancer. Lancet. 1993;342:60-61.
PUBMED
82. Bluming AZ, Wile AG, Schain W, et al. Hormone replacement therapy in women with previously treated primary breast cancer. American Society of Clinical Oncologists, May 14-17, 1994; Dallas, Tex. Abstract.
|
